Nuvectis Pharma Stock (NASDAQ:NVCT)

Ownership Financials Chart

Previous Close

$10.31

52W Range

$5.55 - $13.34

50D Avg

$9.47

200D Avg

$7.85

Market Cap

$278.78M

Avg Vol (3M)

$80.14K

Beta

-0.07

Div Yield

NVCT Company Profile

Nuvectis Pharma, Inc. operates as a biopharmaceutical firm specializing in the development of targeted therapies to address critical, unmet needs within the field of oncology. The company's innovative pipeline features NXP800, a novel compound engineered to inhibit the heat shock factor 1 pathway for treating various forms of cancer. Another promising asset is NXP900, a small molecule drug candidate crafted to suppress the Proto-oncogene c-Src and YES1 kinases. This Fort Lee, New Jersey-based organization was established in 2020.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

IPO Date

Feb 04, 2022

Website

NVCT Performance

NVCT Financial Summary

	Dec 25	Dec 24	Dec 23
Revenue	-	-	-
Operating Income	-	$-19.85M	$-22.90M
Net Income	$-28.87M	$-19.00M	$-22.26M
EBITDA	-	$-19.00M	$-22.90M
Basic EPS	$-1.32	$-1.11	$-1.43
Diluted EPS	$-1.32	$-1.11	$-1.43

Fiscal year ends in Dec 25 | Currency in USD

Peer Comparison

Ticker	Company
MIST	Milestone Pharmaceuticals Inc.
MOLN	Molecular Partners AG
TNXP	Tonix Pharmaceuticals Holding Corp.
CRDF	Cardiff Oncology, Inc.
RANI	Rani Therapeutics Holdings, Inc.
IPHA	Innate Pharma S.A.
CGEN	Compugen Ltd.
SAVA	Cassava Sciences, Inc.